1.20

9.09% 0.10

Pre-market: 1.21 0.01 +0.83%

Quince Therapeutics Inc (QNCX)

Overview News Price History Option Chain Financials Discussions Forecast

Quince Therapeutics Inc stock is traded at $1.20, with a volume of 1.79M. It is up +9.09% in the last 24 hours and down -11.76% over the past month. Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.

Previous Close:

$1.10

Open:

$1.07

24h Volume:

1.79M

Relative Volume:

0.33

Market Cap:

$23.47M

Revenue:

Net Income/Loss:

$-83.98M

P/E Ratio:

-0.0899

EPS:

-13.3519

Net Cash Flow:

$-41.78M

1W Performance:

+12.15%

1M Performance:

-11.76%

6M Performance:

-96.52%

1Y Performance:

-89.19%

1-Day Range:

$1.06

$1.28

1-Week Range:

$1.0091

$1.28

52-Week Range:

$0.79

$45.50

Quince Therapeutics Inc Stock (QNCX) Company Profile

Name

Quince Therapeutics Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

415-910-5717

Address

611 GATEWAY BLVD., SUITE 273, SOUTH SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2026-05-12

Latest SEC Filings

QNCX's Discussions on Twitter

Compare QNCX vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
QNCX Quince Therapeutics Inc	1.20	21.52M	0	-83.98M	-41.78M	-13.35
VRTX Vertex Pharmaceuticals Inc	435.93	110.28B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	634.62	66.98B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	808.43	50.15B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	295.50	39.71B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	154.89	32.22B	742.00K	-1.37B	-1.07B	-7.0731

Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-26	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Aug-05-25	Initiated	Citizens JMP	Mkt Outperform
Mar-24-25	Initiated	Oppenheimer	Outperform

Quince Therapeutics Inc Stock (QNCX) Latest News

May 23, 2026

$Quince Therapeutics (QNCX.US)$ - Moomoo

May 23, 2026

May 22, 2026

Deal Watch: Quince Moves Into Inhaled Respiratory Disease With Orphai Acquisition - Citeline News & Insights

May 22, 2026

QNCX Stock Chart | QUINCE THERAPEUTICS INC (NASDAQ:QNCX) - ChartMill

May 22, 2026

May 21, 2026

Quince Therapeutics regains compliance with Nasdaq listing requirements - Investing.com

May 21, 2026

Quince regains Nasdaq compliance after reporting $15.7M stockholders' equity - TradingView

May 21, 2026

[8-K] Quince Therapeutics, Inc. Reports Material Event - Stock Titan

May 21, 2026

May 19, 2026

Why is QNCX stock up 60% pre-market after a near-total wipeout? - MSN

May 19, 2026

Time is ripe for Quince with Orphai buy and $187m financing - The Pharma Letter

Quince Therapeutics Inc (QNCX)

Quince Therapeutics Inc Stock (QNCX) Company Profile

Compare QNCX vs VRTX, REGN, ARGX, ALNY, RVMD

Quince Therapeutics Inc Stock (QNCX) Upgrades & Downgrades

Quince Therapeutics Inc Stock (QNCX) Latest News

$Quince Therapeutics (QNCX.US)$ - Moomoo

Deal Watch: Quince Moves Into Inhaled Respiratory Disease With Orphai Acquisition - Citeline News & Insights

QNCX Stock Chart | QUINCE THERAPEUTICS INC (NASDAQ:QNCX) - ChartMill

Quince Therapeutics regains compliance with Nasdaq listing requirements - Investing.com

Quince regains Nasdaq compliance after reporting $15.7M stockholders' equity - TradingView

[8-K] Quince Therapeutics, Inc. Reports Material Event - Stock Titan

Why is QNCX stock up 60% pre-market after a near-total wipeout? - MSN

Time is ripe for Quince with Orphai buy and $187m financing - The Pharma Letter

QNCX Stock Price, Quote & Chart | QUINCE THERAPEUTICS INC (NASDAQ:QNCX) - ChartMill

Quince Therapeutics (QNCX) Expands Pipeline with Acquisition of - GuruFocus

Quince Therapeutics (QNCX) Reveals Positive Phase 2a Results for LAM-001 - GuruFocus

Quince Therapeutics, Inc. (QNCX) OrphAI Therapeutics IncM&A CallSlideshow (NASDAQ:QNCX) 2026-05-18 - Seeking Alpha

LAM-001 trial shows gains in PH-ILD patients for Quince Therapeutics (QNCX) - Stock Titan

Quince reports phase 2a data for LAM-001 in lung disease By Investing.com - Investing.com Australia

QNCX Stock Slides As Traders React To Volatile Price Action - StocksToTrade

Quince acquires Orphai, raises $115M in private placement - Investing.com UK

Quince reports phase 2a data for LAM-001 in lung disease - Investing.com UK

Quince Therapeutics reports phase 2a data for LAM-001 in PH-ILD By Investing.com - Investing.com South Africa

Quince acquires Orphai, raises $115M in private placement By Investing.com - Investing.com South Africa

Quince Therapeutics announces LAM-001 data - TipRanks

Quince Therapeutics Closes Orphai Deal and Secures Funding - TipRanks

QNCX: Acquisition and financing secure LAM-001’s development for rare pulmonary diseases through 2028 - TradingView

UPDATEQuince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - The Manila Times

Quince announces acquisition of Orphai and up to $187 million private placement to advance pulmonary pipeline - marketscreener.com

Quince Therapeutics Acquires Orphai and Secures $187M Financing to Advance Pulmonary Rapamycin Pipeline - Minichart

Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD - The Manila Times

Quince Therapeutics reports phase 2a data for LAM-001 in PH-ILD - Investing.com Canada

Quince Therapeutics Stock Faces Nasdaq Pressure After Fresh QNCX Filing - TechStock²

Quince Therapeutics (QNCX) acquires Orphai and secures up to $187M PIPE - Stock Titan

Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline - marketscreener.com

Quince Therapeutics Announces Clinically Meaningful - GlobeNewswire

QNCX Stock Slides As Traders Weigh Cash Runway And Volatility - timothysykes.com

Quince Therapeutics, Inc. acquired OrphAI Therapeutics Inc for $80.9 million. - marketscreener.com

Quince Therapeutics, Inc. announced that it expects to receive $115.000298 million in funding - marketscreener.com

QNCX Should I Buy - Intellectia AI

Nantahala Capital (QNCX) reports 4.53M shares, 7.52% stake disclosed - Stock Titan

Quince Therapeutics (QNCX) price target increased by 100.00% to 81.60 - MSN

Quince Therapeutics stock (US74833Q1004): Analysts see 345% upside potential - AD HOC NEWS

Quince Therapeutics (QNCX) price target increased by 900.00% to 40.80 - MSN

TradingKey - TradingKey

QUE THERAPEUTICS ($QNCX) Releases Q1 2026 Earnings - Moomoo

Quince Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com

Trial setback and cash strain shape Quince (NASDAQ: QNCX) Q1 update - Stock Titan

Quince Therapeutics Inc expected to post a loss of $2.56 a shareEarnings Preview - TradingView

MSN Money - MSN

Quince Therapeutics Inc Stock (QNCX) Financials Data

Revenue

Net Income

Cash Flow

EPS

Similar to QNCX